论文部分内容阅读
目的:探讨子宫肌腺症采用米非司酮治疗的临床效果。方法:选择我院2009年5月至2011年5月收治的子宫肌腺症患者60例,随机分为两组,对照组30例采用甲基睾丸素治疗,观察组30例采用米非司酮治疗,就两组临床资料进行回顾性分析。结果:两组子宫体积及子宫肌瘤在治疗后均明显缩小(P<0.05),观察组缩小幅度明显优于对照组(P<0.05)。两组血红蛋白治疗后较治疗前均有所上升(P<0.05),但组间比较无明显差异(P>0.05)。观察组停药后月经量不多、稀发2例,无阴道出血。对照组阴道少量出血2例,经期缩短3例。随访观察组贫血均有效纠正,对照组贫血纠正24例。观察组有效率为86.6%,对照组有效率为66.7%,观察组诱导闭经14例,对照组3例,观察组优于对照组有效率、纠正贫血率、诱导闭经率(P<0.05)。结论:子宫肌腺症采用米非司酮治疗,可降低并发症发生率,提高临床治疗效果,明显改善患者生存质量
Objective: To investigate the clinical effect of mifepristone treatment in uterine adenomyosis. Methods: Sixty patients with myasthenia gravis admitted to our hospital from May 2009 to May 2011 were randomly divided into two groups. The control group was treated with methyltestosterone. Thirty patients in the observation group were treated with mifepristone Treatment, the two groups of clinical data were retrospectively analyzed. Results: The volume of uterine fibroids and uterine fibroids in both groups were significantly decreased after treatment (P <0.05), and the reduction in observation group was significantly better than that in control group (P <0.05). Hemoglobin in both groups increased after treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). Observed group after stopping small amount of menstruation, thin hair in 2 cases, no vaginal bleeding. The control group, 2 cases of vaginal bleeding, menstrual shortening in 3 cases. Follow-up observation group were effectively corrected anemia, anemia in the control group corrected 24 cases. The effective rate was 86.6% in the observation group and 66.7% in the control group. In the observation group, 14 cases were amenorrhea and 3 cases in the control group. The observation group was superior to the control group in correcting the anemia rate and inducing amenorrhea rate (P <0.05). Conclusion: Mifepristone treatment of uterine adenomyosis can reduce the incidence of complications and improve the clinical treatment effect, significantly improve the quality of life of patients